Literature DB >> 11742250

Lower dopamine transporter binding potential in striatum during depression.

J H Meyer1, S Krüger, A A Wilson, B K Christensen, V S Goulding, A Schaffer, C Minifie, S Houle, D Hussey, S H Kennedy.   

Abstract

Previous studies suggest that there is a dopamine lowering process during major depressive episodes (MDE). To investigate this, we measured the dopamine transporter binding potential (DAT BP) in the striatum of depressed and healthy subjects using [(11)C]RTI-32 PET. The DAT, a predominantly presynaptic receptor, decreases in density after chronic dopamine depletion and the BP is proportional to receptor density. In all striatal regions, subjects with MDE had significantly lower DAT BP. Low striatal DAT BP in MDE is consistent with a downregulation of DAT in response to a dopamine lowering process. There was also a strong, highly significant, inverse correlation between striatal DAT BP and neuropsychological tests of dopamine-implicated symptoms in patients (i.e. patients with lower DAT BP performed better). Lower DAT BP itself reduces extracellular clearance of dopamine. Patients who did not decrease their striatal DAT BP failed to compensate for low dopamine and showed greater impairment on dopamine related tests.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742250     DOI: 10.1097/00001756-200112210-00052

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  59 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I.

Authors:  H Umesha Shetty; Sami S Zoghbi; Jeih-San Liow; Masanori Ichise; Jinsoo Hong; John L Musachio; Christer Halldin; Jurgen Seidel; Robert B Innis; Victor W Pike
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-10       Impact factor: 9.236

3.  Pathophysiology of depression: do we have any solid evidence of interest to clinicians?

Authors:  Gregor Hasler
Journal:  World Psychiatry       Date:  2010-10       Impact factor: 49.548

Review 4.  Positron emission tomography molecular imaging in late-life depression.

Authors:  Kentaro Hirao; Gwenn S Smith
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-01-05       Impact factor: 2.680

5.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

Review 6.  [The significance of stress: its role in the auditory system and the pathogenesis of tinnitus].

Authors:  B Mazurek; T Stöver; H Haupt; B F Klapp; M Adli; J Gross; A J Szczepek
Journal:  HNO       Date:  2010-02       Impact factor: 1.284

Review 7.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 8.  Molecular imaging in patients with mood disorders: a review of PET findings.

Authors:  Qiaozhen Chen; Weibo Liu; Huichun Li; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

9.  Elevated prolactin responses to L-tryptophan infusion in medication-free depressed patients.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Margaret S Smith; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2003-05-01       Impact factor: 4.530

10.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.